North America Associated Press
UCB Announces Breakthrough Data on KYGEVVI Therapy for Rare Genetic Disorder TK2d.1
UCB announces publication of data demonstrating positive impact of KYGEVVI therapy in patients with Thymidine Kinase 2 Deficiency (TK2d), showing improved survival and functional outcomes.
Read summary